Your session is about to expire
← Back to Search
Monoclonal Antibodies
DS-8273a & Nivolumab for Melanoma
Phase 1
Waitlist Available
Led By Jeffrey Weber, MD, PhD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
Summary
The purpose of this study is to evaluate the safety profile, tolerability, and immunoregulatory (pharmacodynamic; PD) activity of DS-8273a administered in combination with nivolumab (anti-PD-1 antibody) to subjects with unresectable Stage III or Stage IV melanoma.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Safety (adverse events) of the protocol therapy
Secondary study objectives
Anti-tumor activity of the protocol therapy
Trial Design
1Treatment groups
Experimental Treatment
Group I: DS-8273a & NivolumabExperimental Treatment2 Interventions
Patient groups (cohorts) will receive a single dose level of DS 8273a \& Nivolumab; DS 8273a will be increased in subsequent cohorts.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DS-8273a
2014
Completed Phase 1
~50
Nivolumab
FDA approved
Find a Location
Who is running the clinical trial?
Daiichi SankyoIndustry Sponsor
404 Previous Clinical Trials
447,932 Total Patients Enrolled
4 Trials studying Melanoma
497 Patients Enrolled for Melanoma
NYU Langone HealthLead Sponsor
1,397 Previous Clinical Trials
861,763 Total Patients Enrolled
11 Trials studying Melanoma
342 Patients Enrolled for Melanoma
Daiichi Sankyo, Inc.Industry Sponsor
389 Previous Clinical Trials
422,660 Total Patients Enrolled
4 Trials studying Melanoma
497 Patients Enrolled for Melanoma
Share this study with friends
Copy Link
Messenger